Compare Biocon with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NEULAND LABS - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NEULAND LABS BIOCON /
NEULAND LABS
 
P/E (TTM) x 31.8 53.9 59.1% View Chart
P/BV x 3.8 4.1 93.0% View Chart
Dividend Yield % 0.3 0.1 292.6%  

Financials

 BIOCON    NEULAND LABS
EQUITY SHARE DATA
    BIOCON
Mar-19
NEULAND LABS
Mar-20
BIOCON /
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs707754 93.9%   
Low Rs554247 223.9%   
Sales per share (Unadj.) Rs91.9594.5 15.5%  
Earnings per share (Unadj.) Rs16.712.6 132.3%  
Cash flow per share (Unadj.) Rs24.237.0 65.3%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.4 39.7%  
Book value per share (Unadj.) Rs101.6553.4 18.4%  
Shares outstanding (eoy) m600.0012.83 4,676.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.90.8 815.0%   
Avg P/E ratio x37.739.6 95.3%  
P/CF ratio (eoy) x26.113.5 192.9%  
Price / Book Value ratio x6.20.9 686.0%  
Dividend payout %6.015.8 37.8%   
Avg Mkt Cap Rs m378,3306,421 5,892.3%   
No. of employees `0006.11.3 478.2%   
Total wages/salary Rs m11,6531,236 943.1%   
Avg. sales/employee Rs Th8,994.35,949.4 151.2%   
Avg. wages/employee Rs Th1,900.7963.8 197.2%   
Avg. net profit/employee Rs Th1,635.3126.4 1,293.5%   
INCOME DATA
Net Sales Rs m55,1447,627 723.0%  
Other income Rs m1,44439 3,716.9%   
Total revenues Rs m56,5887,666 738.2%   
Gross profit Rs m15,8831,019 1,558.9%  
Depreciation Rs m4,478313 1,431.6%   
Interest Rs m709216 328.7%   
Profit before tax Rs m12,140529 2,294.0%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123367 578.3%   
Profit after tax Rs m10,026162 6,185.8%  
Gross profit margin %28.813.4 215.6%  
Effective tax rate %17.569.4 25.2%   
Net profit margin %18.22.1 855.6%  
BALANCE SHEET DATA
Current assets Rs m48,2285,152 936.1%   
Current liabilities Rs m30,3763,576 849.4%   
Net working cap to sales %32.420.7 156.7%  
Current ratio x1.61.4 110.2%  
Inventory Days Days68105 65.0%  
Debtors Days Days8691 94.1%  
Net fixed assets Rs m64,1303,969 1,616.0%   
Share capital Rs m3,000129 2,325.6%   
"Free" reserves Rs m57,9806,971 831.8%   
Net worth Rs m60,9807,100 858.9%   
Long term debt Rs m15,766774 2,037.7%   
Total assets Rs m121,92412,310 990.5%  
Interest coverage x18.13.5 524.8%   
Debt to equity ratio x0.30.1 237.2%  
Sales to assets ratio x0.50.6 73.0%   
Return on assets %8.83.1 286.9%  
Return on equity %16.42.3 720.2%  
Return on capital %16.89.5 177.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5065,187 299.0%   
Fx outflow Rs m10,3991,593 652.9%   
Net fx Rs m5,1073,594 142.1%   
CASH FLOW
From Operations Rs m11,546573 2,013.6%  
From Investments Rs m-7,138-487 1,466.3%  
From Financial Activity Rs m-2,417-55 4,410.6%  
Net Cashflow Rs m2,10333 6,450.9%  

Share Holding

Indian Promoters % 40.4 36.3 111.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 63.7 13.2%  
FIIs % 10.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 63.7 31.2%  
Shareholders   109,995 12,705 865.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   JUBILANT PHARMOVA   PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 12, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS